A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: demolition (5), ruin (2), damage (326)

Records management policy

Description
Records Management Policy Date Issued: Review Date: Document Type: 9 May 2018 19 April 2021 Policy Version: 6 Contents Paragraph 1 2
Url
/Media/UHS-website-2019/Docs/Policies/Records-management-policy.pdf

ACCORD-2 example sub-protocol

Description
CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

Prof Tim Elliott, experimental oncology

Description
NIHR CRUK Experimental Cancer Medicine Centre Auto Generated Title Professor Elliott ’ s research looks at how the body prepares viruses a
Url
/ClinicalResearchinSouthampton/Our-people/Cancer-research-people/Prof-Tim-Elliott.aspx

Data protection and confidentiality policy

Description
University Hospitals Southampton NHS Foundation Trust needs to collect and use information about people with whom it deals in order to
Url
/Media/UHS-website-2019/Docs/Policies/Data-protection-and-confidentiality-policy.pdf

Needle phobia

Description
Patients do not often disagree with the clinician who is treating them. When disagreement occurs, under some circumstances, this may lead
Url
/HealthProfessionals/Clinical-law-updates/Needle-phobia.aspx

Acalabrutinib

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Regimen Acalabrutinib • CLL – Acalabrutinib Indication • First-line treatment of chronic lymphocytic leukaemia (CLL) prior to E
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Acalabrutinib.pdf

ACCORD-2 master protocol

Description
CONFIDENTIAL ACCORD-2-001 – Master Protocol TITLE PAGE Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study
Url
/Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-master-protocol.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory/relapsed euroblastoma Version 8.0 dated 07-Mar-2023 Dinutuximab beta amendment Coordinating Sponsor: Sponsor Protocol Number: CAS Code: EudraCT Number: ISRCTN Reference Number: ITCC Number: Roche Study Reference Number: Email: University of Birmingham RG_ 11-087 BN2008 2012-000072-42 40708286 032 MO28245 beacon@trials.bham.ac.uk This application is supported by the facilities funded thro
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf
1 to 8 of 8